LT3389699T - Chimeriniai ir humanizuoti monokloniniai antikūnai prieš žmogaus ctla4 ir jų panaudojimas - Google Patents

Chimeriniai ir humanizuoti monokloniniai antikūnai prieš žmogaus ctla4 ir jų panaudojimas

Info

Publication number
LT3389699T
LT3389699T LTEPPCT/US2016/066698T LTUS2016066698T LT3389699T LT 3389699 T LT3389699 T LT 3389699T LT US2016066698 T LTUS2016066698 T LT US2016066698T LT 3389699 T LT3389699 T LT 3389699T
Authority
LT
Lithuania
Prior art keywords
chimeric
monoclonal antibodies
humanized anti
human ctla4
ctla4 monoclonal
Prior art date
Application number
LTEPPCT/US2016/066698T
Other languages
English (en)
Lithuanian (lt)
Inventor
Yang Liu
Pan Zheng
Martin DEVENPORT
Original Assignee
OncoC4, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OncoC4, Inc. filed Critical OncoC4, Inc.
Publication of LT3389699T publication Critical patent/LT3389699T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/US2016/066698T 2015-12-15 2016-12-14 Chimeriniai ir humanizuoti monokloniniai antikūnai prieš žmogaus ctla4 ir jų panaudojimas LT3389699T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562267735P 2015-12-15 2015-12-15
US201662309169P 2016-03-16 2016-03-16
US201662359036P 2016-07-06 2016-07-06
PCT/US2016/066698 WO2017106372A1 (en) 2015-12-15 2016-12-14 Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof

Publications (1)

Publication Number Publication Date
LT3389699T true LT3389699T (lt) 2024-06-10

Family

ID=59057509

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2016/066698T LT3389699T (lt) 2015-12-15 2016-12-14 Chimeriniai ir humanizuoti monokloniniai antikūnai prieš žmogaus ctla4 ir jų panaudojimas

Country Status (26)

Country Link
US (3) US10618960B2 (enExample)
EP (2) EP3389699B1 (enExample)
JP (4) JP6858779B2 (enExample)
KR (2) KR20250108763A (enExample)
CN (2) CN116063492A (enExample)
AU (2) AU2016370648B2 (enExample)
BR (1) BR112018012113A2 (enExample)
CA (1) CA3006984C (enExample)
DK (1) DK3389699T5 (enExample)
ES (1) ES2979210T3 (enExample)
FI (1) FI3389699T3 (enExample)
HR (1) HRP20240719T1 (enExample)
HU (1) HUE066907T2 (enExample)
IL (3) IL259988B2 (enExample)
LT (1) LT3389699T (enExample)
MX (3) MX2018006925A (enExample)
MY (1) MY186974A (enExample)
PL (1) PL3389699T3 (enExample)
PT (1) PT3389699T (enExample)
RS (1) RS65703B1 (enExample)
SG (1) SG11201804969PA (enExample)
SI (1) SI3389699T1 (enExample)
SM (1) SMT202400211T1 (enExample)
TW (1) TWI739781B (enExample)
WO (1) WO2017106372A1 (enExample)
ZA (1) ZA201804077B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3303394T1 (sl) 2015-05-29 2020-10-30 Agenus Inc. Protitelesa proti-CTLA-4 in postopki njihove uporabe
EP3515489B1 (en) * 2016-09-19 2025-11-05 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof
IL266918B2 (en) 2016-12-07 2024-03-01 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
WO2019094637A1 (en) * 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US12129299B2 (en) 2018-02-02 2024-10-29 OncoC4, Inc. Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
SG11202007018QA (en) * 2018-02-02 2020-08-28 Oncoimmune Inc Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
CN115991787A (zh) 2018-06-05 2023-04-21 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
CN119930820A (zh) * 2018-12-27 2025-05-06 吉加根公司 抗ctla-4结合蛋白及其使用方法
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
KR20220166795A (ko) * 2020-04-13 2022-12-19 바이오션, 인코포레이티드 Ctla4에 결합하는 항체 및 이의 용도
WO2021220251A1 (en) 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2022169269A1 (ko) * 2021-02-03 2022-08-11 주식회사 유틸렉스 항 ctla-4 항체 및 이의 용도
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
WO2022214653A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
JP7345889B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
EP4392156A4 (en) * 2021-10-08 2025-06-25 Kashiv Biosciences, LLC Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
CA3234491A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
MX2024004429A (es) 2021-10-29 2024-05-06 Oncoc4 Inc Regimenes de dosificacion del anticuerpo anti-ctla-4.
EP4431528A1 (en) * 2021-10-29 2024-09-18 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
CN119947752A (zh) 2022-09-16 2025-05-06 昂科医药 抗ctla-4抗体用于治疗腺样囊性癌的用途
CN120981564A (zh) 2023-03-17 2025-11-18 圭尔医疗有限公司 调节性t细胞疗法
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024227176A1 (en) 2023-04-28 2024-10-31 OncoC4, Inc. Combinations of anti-ctla-4 antibodies and anti-pd-1 antibodies and therapeutic uses thereof
WO2024254403A2 (en) * 2023-06-09 2024-12-12 The Regents Of The University Of California Methods for identifying and correcting tumor humoral immune dysfunction
WO2025133186A1 (en) 2023-12-22 2025-06-26 OncoC4, Inc. Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK1210428T3 (en) 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
IL148021A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
AU2002258941A1 (en) 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
EP1793857A4 (en) * 2004-09-08 2008-09-03 Univ Ohio State Res Found COMBINED THERAPY USING ANTI-CTLA4 ANTI-4-1BB ANTIBODIES
EP1793858A4 (en) * 2004-09-08 2008-12-10 Univ Ohio State Res Found HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
CN104104517B (zh) 2004-10-15 2017-11-07 弗里塞恩公司 一次性密码验证的方法和系统
CN101146826A (zh) 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
EP2418278A3 (en) * 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
CN101628940B (zh) * 2008-07-15 2011-11-23 中国科学院生物物理研究所 一种单克隆抗体及其应用
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2013142796A2 (en) * 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104292334B (zh) * 2014-04-25 2018-11-27 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
EP3515489B1 (en) 2016-09-19 2025-11-05 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof

Also Published As

Publication number Publication date
US11629188B2 (en) 2023-04-18
JP2019510733A (ja) 2019-04-18
MX2025001300A (es) 2025-03-07
TW201731877A (zh) 2017-09-16
EP3389699B1 (en) 2024-05-01
IL259988B (en) 2022-10-01
CN116063492A (zh) 2023-05-05
SI3389699T1 (sl) 2024-07-31
US20230391870A1 (en) 2023-12-07
ZA201804077B (en) 2019-09-25
KR20180086219A (ko) 2018-07-30
KR20250108763A (ko) 2025-07-15
IL310404A (en) 2024-03-01
FI3389699T3 (fi) 2024-05-28
MX2025001302A (es) 2025-03-07
US20190127468A1 (en) 2019-05-02
EP4374926A2 (en) 2024-05-29
PL3389699T3 (pl) 2024-07-22
US10618960B2 (en) 2020-04-14
TWI739781B (zh) 2021-09-21
CA3006984A1 (en) 2017-06-22
AU2023203169B2 (en) 2025-11-27
IL259988B2 (en) 2023-02-01
AU2016370648B2 (en) 2023-03-09
BR112018012113A2 (pt) 2018-12-04
AU2023203169A1 (en) 2023-06-15
CN108430499A (zh) 2018-08-21
WO2017106372A1 (en) 2017-06-22
JP6858779B2 (ja) 2021-04-14
NZ743013A (en) 2025-03-28
IL259988A (en) 2018-07-31
IL296354B1 (en) 2024-03-01
SMT202400211T1 (it) 2024-07-09
JP2021100957A (ja) 2021-07-08
US12473362B2 (en) 2025-11-18
ES2979210T3 (es) 2024-09-24
JP2023106547A (ja) 2023-08-01
US20200283526A1 (en) 2020-09-10
IL296354A (en) 2022-11-01
IL296354B2 (en) 2024-07-01
RS65703B1 (sr) 2024-07-31
DK3389699T3 (da) 2024-05-13
CN108430499B (zh) 2022-07-19
PT3389699T (pt) 2024-06-04
JP2022123049A (ja) 2022-08-23
HUE066907T2 (hu) 2024-09-28
CA3006984C (en) 2023-10-17
KR102830926B1 (ko) 2025-07-08
JP2025160458A (ja) 2025-10-22
AU2016370648A1 (en) 2018-06-21
SG11201804969PA (en) 2018-07-30
MX2018006925A (es) 2018-08-01
HRP20240719T1 (hr) 2024-09-13
EP3389699A1 (en) 2018-10-24
EP3389699A4 (en) 2019-07-10
DK3389699T5 (da) 2024-09-23
JP7286845B2 (ja) 2023-06-05
MY186974A (en) 2021-08-26
EP4374926A3 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
ZA201804077B (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
IL311371A (en) CD3 antibodies of human origin or chimeras
IL283812A (en) Humanized antibody against human pd–1
IL288457A (en) Humanized anti-human CD19 antibodies and methods of use
IL255207B1 (en) Myeloma antigen chimeric antigen receptors and their uses
SG11201509609SA (en) Chimeric antigen receptor-targeting monoclonal antibodies
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
EP3466974A4 (en) HUMANIZED MONOCLONAL ANTI-HUMAN PD-1 ANTIBODY AND USE THEREOF
IL263936A (en) Humanized monoclonal antibodies targeting hptp-beta)ve-ptp)
IL282756A (en) Humanized antibodies against SIRPα
ZA201807167B (en) Humanized anti-il-1r3 antibodies
EP3131917A4 (en) Humanized and chimeric monoclonal antibodies to cd99
HK40092659A (zh) 嵌合和人源化抗人类ctla4单克隆抗体和其用途
HK40111469A (zh) 人源化或嵌合cd3抗体
HK1255635A1 (zh) 人源化或嵌合的cd3抗体